SCHEMBL5285381

SCHEMBL5285381

CC1(C)CCN(S(=O)(=O)c2c(Cl)ccc3nonc23)CC1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.58
NPC1 O15118 1/20 0.58
TLR9 Q9NR96 1/20 0.58
ALDH1A1 P00352 7/20 0.41
MEN1 O00255 4/20 0.41
MAPT P10636 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.37
CCR1 P32246 1/20 0.37
HPGD P15428 2/20 0.36
HTT P42858 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5286862 0.82 LMNA (0.43) KMT2ANPC1TLR9ALDH1A1MEN1
SCHEMBL5244644 0.80 KMT2A (0.62) KMT2ANPC1TLR9ALDH1A1MEN1
SCHEMBL5288051 0.79 KMT2A (0.57) KMT2ANPC1TLR9ALDH1A1MEN1
SCHEMBL6390882 0.78 NPC1 (0.47) KMT2ANPC1TLR9
SCHEMBL5280469 0.78 NPC1 (0.47) KMT2ANPC1TLR9
SCHEMBL5242980 0.75 KMT2A (0.53) KMT2ANPC1TLR9ALDH1A1MEN1
SCHEMBL18575963 0.74 KMT2A (0.48) KMT2ANPC1TLR9ALDH1A1MEN1
SCHEMBL5281618 0.73 KMT2A (0.49) KMT2ANPC1TLR9ALDH1A1MEN1
SCHEMBL1022338 0.73 KMT2A (0.46) KMT2ANPC1TLR9ALDH1A1MEN1
SCHEMBL5292223 0.72 ALDH1A1 (0.50) KMT2ANPC1TLR9ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP KMT2A 1303/4885NPC1 1567/4885TLR9 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.